Inovio Pharmaceuticals
184 hedge funds and large institutions have $196M invested in Inovio Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 67 increasing their positions, 36 reducing their positions, and 32 closing their positions.
86% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 36
0.67% more ownership
Funds ownership: 3.46% → 4.13% (+0.67%)
7% less funds holding
Funds holding: 198 → 184 (-14)
24% less call options, than puts
Call options by funds: $2.14M | Put options by funds: $2.82M
34% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 32
41% less capital invested
Capital invested by funds: $330M → $196M (-$134M)
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$21M |
| 2 |
Two Sigma Advisers
New York
|
+$6.72M |
| 3 |
Two Sigma Investments
New York
|
+$5.26M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.99M |
| 5 |
BlackRock
New York
|
+$4.41M |
Top Sellers
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2.43M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.51M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$1.02M |
| 4 |
JF
Jump Financial
Chicago,
Illinois
|
-$468K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$441K |
INO Hedge Fund Activity: Q2 2022 in Review
184 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q2 2022, worth a combined $196M — down 41% from $330M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of INO and 21 opened new positions — a net loss of 11 holders — while 36 trimmed existing stakes and 67 added.
The largest buyer was State Street, adding an estimated $21M. The largest seller was UBS Group, cutting an estimated $2.43M.
- 184 institutional investors held Inovio Pharmaceuticals (INO) as of Q2 2022, down from 198 in Q1 2022.
- Funds reported $196M of Inovio Pharmaceuticals stock for Q2 2022, down 41% quarter-over-quarter.
- 21 funds opened new Inovio Pharmaceuticals positions in Q2 2022 and 32 closed out, a net change of -11 holders.
- The largest Inovio Pharmaceuticals buyer in Q2 2022 was State Street, an estimated $21M added.
- The largest Inovio Pharmaceuticals seller in Q2 2022 was UBS Group, an estimated $2.43M sold.
Based on aggregated 13F filings for Q2 2022.